Form 4: Haemonetics Director Mark Kroll Awarded 2,693 Restricted Stock Units

Haemonetics Corporation Director Mark W. Kroll was awarded 2,693 restricted stock units as part of the company's long-term incentive compensation plan.

Summary

• Mark W. Kroll, a Director of Haemonetics Corp (HAE), was awarded 2,693 shares of common stock in the form of Restricted Stock Units (RSUs).
• The transaction occurred on July 24, 2025.
• These RSUs were issued under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting.
• The RSUs will vest 100% on the first anniversary of the grant date.
• Following this transaction, Mark W. Kroll beneficially owns 23,357 shares directly.

Sentiment

Score: 7

Explanation: The award of Restricted Stock Units to a director is a positive signal, aligning management incentives with shareholder interests and demonstrating commitment to the company's long-term performance. It's a standard compensation practice.

Positives

• Award of 2,693 Restricted Stock Units to a Director aligns management incentives with shareholder interests.
• The award is part of a pre-existing, approved long-term incentive compensation plan (2019 Long-Term Incentive Compensation Plan), indicating structured governance.
• The vesting schedule (100% on first anniversary) encourages long-term commitment and performance.

Risks

• The value of the awarded RSUs is contingent on the future performance of Haemonetics Corporation's common stock.
• Non-vesting risk if the recipient leaves the company before the vesting date.

Future Outlook

The awarded Restricted Stock Units are set to vest 100% on the first anniversary of the grant date, aligning the director's future compensation with the company's long-term performance.

Industry Context

The award of Restricted Stock Units to a director is a common practice in publicly traded companies across various industries, including the medical technology sector where Haemonetics operates. This method of compensation is widely used to align the interests of directors and executives with those of shareholders by tying a portion of their compensation to the company's stock performance.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) for director compensation is a standard practice across the medical technology and broader corporate landscape, comparable to companies like Medtronic (MDT) or Abbott Laboratories (ABT) which also utilize equity-based incentive plans to retain and motivate key personnel.
• The vesting schedule of 100% on the first anniversary is a common structure for director RSU grants, aiming to ensure continued engagement and long-term value creation, similar to practices observed in other S&P 500 companies.
• The specific number of units awarded (2,693) would need to be benchmarked against the typical RSU grants for directors at companies of similar market capitalization and industry to assess if it's above, below, or in line with peer compensation. Without that specific comparative data in the filing, a precise quantitative comparison is limited, but the mechanism itself is standard.

Corporate Governance

Related Party Transactions

• The transaction involves the award of equity compensation to a Director, Mark W. Kroll, which constitutes a related party transaction as it is between the company and a member of its board. This is a standard and disclosed form of related party compensation.

Stakeholder Impact

• Shareholders: The RSU award aligns the director's financial interests with shareholder value creation, as the value of the RSUs is tied to the company's stock performance. It also represents a dilution of existing shares upon vesting, though typically minor for individual grants.
• Employees: No direct impact on general employees is indicated, but it reinforces the company's commitment to equity-based compensation for key personnel.

Next Steps

• The 2,693 Restricted Stock Units are expected to vest 100% on the first anniversary of the grant date, which is July 24, 2026.

Key Dates

Recommendation

This Form 4 filing reports a routine equity award to a director as part of a pre-existing compensation plan. While it's a minor positive for aligning incentives, it does not provide new material information about the company's financial performance, strategic direction, or market position that would warrant a change in investment recommendation. It's an expected operational disclosure.

Keywords

Haemonetics Corp, HAE, Mark Kroll, Director, Restricted Stock Units, RSUs, Stock Award, Compensation, Insider Transaction, SEC Form 4, Long-Term Incentive Plan